Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Makers of dietary supplements are pushing the Food and Drug Administration to expand the types of ingredients they can put in their products, a change that could open the way for the marketing of peptides, probiotics and other cutting-edge health offerings. The FDA held a public meeting on Friday to discuss the long-term criteria for … Read more

Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Makers of dietary supplements are pushing the Food and Drug Administration to expand the types of ingredients they can put in their products, a change that could open the way for the marketing of peptides, probiotics and other cutting-edge health offerings. The FDA held a public meeting on Friday to discuss the long-term criteria for … Read more

Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Dietary supplement makers are pushing the FDA to allow peptides and other new ingredients

Makers of dietary supplements are pushing the Food and Drug Administration to expand the types of ingredients they can put in their products, a change that could open the way for the marketing of peptides, probiotics and other cutting-edge health offerings. The FDA held a public meeting on Friday to discuss the long-term criteria for … Read more

Pinnacle Medicines, a pioneer in oral peptide therapeutics, announced an additional $89 million in Series B funding to advance its pipeline into clinical trials.

Pinnacle Medicines, a pioneer in oral peptide therapeutics, announced an additional $89 million in Series B funding to advance its pipeline into clinical trials.

The financing was co-led by LAV and Foresite Capital with participation from existing investors including Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and OrbiMed. The company has raised $134 million to date after incubation by OrbiMed and other healthcare specialist investors. Achievements will support the advancement of the oral peptide pipeline through clinical … Read more